Pharos has also been working with Coalition Plus in Indonesia. Here we are supporting PKNI, the drug user’s network of Indonesia, in developing a preliminary investment case for scale-up. To date, Indonesia has not yet developed a national hepatitis strategy. We are currently modelling several elimination scenarios and estimating the costs and cost-effectiveness of each in order to inform the government’s decision-making process as it seeks to develop a strategy and future targets. PKNI plans to use this work to advise the government in the development of its future policy and to advocate for increased
investment in hepatitis C nationally.
Team members: Lindsey Hiebert, Adam Trickey, Peter Vickerman, Carl Schutte, Rob Hecht